Guillain-Barre Syndrome Treatment
- Plasmapheresis or plasma exchange therapy for Guillain-Barre syndrome:
- Filtering the blood to remove proteins made by the immune system
- Albumin (Albuminar, Albumisol, Albunex, Albutein)
- High-dose immunoglobulin therapy for Guillain-Barre syndrome:
- Large doses of immune system proteins from donors' blood
Guillain-Barre Syndrome Questions For Doctor
The following are some important questions to ask before and after the treatment of Guillain-Barre syndrome.
Questions to ask before treatment:
- What are my treatment options?
- What are the risks associated with treatment?
- Do I need to stay in the hospital?
- How long will I be in the hospital?
- What are the complications I should watch for?
- How long will I be on medication?
- What are the potential side effects of my medication?
- Does my medication interact with nonprescription medicines or supplements?
- Should I take my medication with food?
Questions to ask after treatment:
- Do I need to change my diet?
- Do I need to lose weight?
- Are there any medications or supplements I should avoid?
- When can I resume my normal activities?
- When can I return to work?
- Do I need a special exercise program?
- Will I need physical therapy?
- Will I need occupational therapy?
- How often will I need to see my doctor for checkups?
- What local support and other resources are available?
Guillain-Barre Syndrome Specialist
Physicians from the following specialties evaluate and treat Guillain-Barre syndrome:
Continue to Guillain-Barre Syndrome Warning Signs
- Awong IE, Dandurand KR, Keeys CA, Maung-Gyi FA: Drug-associated Guillain-Barre syndrome: a literature review. Ann Pharmacother 1996 Feb; 30(2): 173-80. 
- Hughes RA, Wijdicks EF, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Sladky JT, Barohn RJ, Stevens JC; Multidisciplinary Consensus Group. Supportive care for patients with guillain-barre syndrome. Arch Neurol. 2005 Aug;62(8):1194-8. 
- van Doorn PA. Treatment of Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst. 2005 Jun;10(2):113-27.